Pacific Biomarkers (PBMC.OB) Posts Financial Results, Impacted by Broader Drug Development Environment

QualityStocks would like to highlight Pacific Biomarkers, Inc. (OTCBB: PBMC). The company provides biomarker laboratory services and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. They provide services in the areas of cardiovascular and musculoskeletal diseases, diabetes, obesity, and nutrition.

In the company’s news yesterday,

Pacific Biomarkers announced its operating results for the second quarter and first half of fiscal year 2011, noting industry challenges and the company’s strategy for overcoming them.

“Our results for the three months ended December 31, 2010, are a reflection of the challenging drug development environment. While revenue increased from the prior year, gross profit was still short of plan. We remain confident that we are well positioned to execute our strategic plan for continued growth in the specialty laboratory and our biomarker services area,” Ron Helm, CEO of Pacific Biomarkers stated in the press release. “We benefited from a large contract in the first two quarters, while other revenues reflected what we have seen in our clinical services market in line with what other Contract Research Organizations (CROs) have reported.”

For the second quarter of fiscal 2011 ended December 31, 2010, revenue increased 20 percent to $2.53 million, compared with $2.11 million the second quarter of fiscal 2010. Operating loss was ($202,728) in the second quarter of fiscal 2011, compared to an operating loss of ($307,037) in the prior-year period. The company posted net loss of ($349,218), or ($0.02) per share, for the three months ended December 31, 2010, compared with net loss of ($457,629), or ($0.03) per share, the comparable three months of fiscal 2010.

Revenue for the six months ended December 31, 2010, increased 22 percent to $5.38 million, compared with $44.41 million during the comparable six months of fiscal 2009. Pacific Biomarkers posted an operating loss was ($250,252) in the first half of fiscal 2011, versus an operating loss of ($520,745) in the same period last year. Net loss for the six months ended December 31, 2010, was reported at ($551,581), or ($0.03) per share, compared with net income of ($730,799), or ($0.04) per share, for the comparable six-month period in fiscal 2010.

“The company’s result last year demonstrated that the drug development marketplace continues to challenge organizations supporting clinical trial work as well as biomarker development. We believe that our strategy of broadening our biomarker services offering continues to be a sound move even in view of somewhat mixed results so far for this fiscal year — down 15 percent for the quarter, but up 4 percent for the six-month period,” Helm stated. “The current market conditions may challenge us for a time and we have implemented measures to control costs including a reduction in force during the second quarter and other operating expense reductions. We believe we will be positioned appropriately as the market improves.”

“We anticipate improvement in demand for our broad portfolio of specialty laboratory and biomarker services. We have identified the biomarker services area as the long-term growth driver in a market segment where demand is strong and there continue to be no dominant players in this area,” concluded Helm.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net

Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.